ACHIEVE
Summary
People receiving dialysis are at risk of heart failure and heart related death. There is an urgent need for treatments that reduce the risk of these problems in the dialysis population.
Spironolactone is a pill used to prevent heart failure and related deaths in patients that do not require dialysis. It works by blocking a hormone (aldosterone) in your body that causes high blood pressure and can damage the heart. Although spironolactone is very effective in people that do not require dialysis, we do not know if spironolactone is effective in those receiving dialysis. Our research will help determine if spironolactone reduces heart failure and heart related deaths in people receiving dialysis.
The purpose of this study is to determine if spironolactone reduces death or hospitalization for heart failure and is well tolerated in people who require dialysis.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 99
Inclusion criteria:
Inclusion criteria
1. Age
a. If no history of diabetes, age at least 45 years, or
b. at least 18 yrs with a history of diabetes
2. On dialysis for at least 90 days
3. On either
a. Hemodialysis and prescribed at least 2 treatments per week or
b. Peritoneal dialysis prescribed with at least 1 exchange daily
4. Provides informed consent
Exclusion criteria:
1. High blood potassium
2. Currently taking spironolactone or eplerenone and unable to stop this medication
3. Known sensitivity or allergy to spironolactone
4. Current or planned pregnancy or breastfeeding
5. Scheduled living related donor kidney transplant
6. Life expectancy less than 6 months in the opinion of a treating kidney doctor.
7. Enrolled in another trial testing a drug similar to spironolactone or a
drug that has a known or likely interaction with spironolactone.
8. Treating physician believes that spironolactone is either absolutely needed or
absolutely the wrong treatment for the patient
Participate
Additional information
Contact information
Dr. Braden Manns 403-944-2595 or Sheilah Heal 403-955-6385
Principal investigator:
Braden Manns
Clinical trial:
Yes
REB-ID:
REB17-0512